CAR-T Therapy Archives - Page 8 of 8 - Cancer Therapy Advisor

CAR-T’s inability to induce durable remissions in many patients is a barrier to the success of these adoptive cell therapies—but solutions are under way.

Understanding the Limitations of CAR-T Cell Therapies

By

April 9, 2019

CAR-T’s inability to induce durable remissions in many patients is a barrier to the success of these adoptive cell therapies—but solutions are under way.

Clinicians continue to learn about which patients will benefit most from different immunotherapy tre

AACR 2019

Novel Toxicities, Anticancer Activity of Anti-CD22 CAR-T Therapies Revealed

By

Susan Moench, PhD, PA-C

April 2, 2019

Hemophagocytic lymphohistiocytosis is a rare, but potentially fatal, complication of immunotherapy, resulting from immune hyperactivation.

Hematologic Cancers, Lymphoma

Severe Neurotoxicity Following CAR-T Cell Therapy Associated With Poor Prognosis

By

Susan Moench, PhD, PA-C

March 11, 2019

CAR-T–related neurotoxicity was found to be associated with the presence of cytokine release syndrome.

The continuous decline in cancer deaths over the past 25 years was attributed to improvements in scr

Hematologic Cancers, Lymphoma, Pediatric Cancer

“Real-World” Hospitalization Data on Patients Receiving CAR-T Cell Therapy

By

Susan Moench, PhD, PA-C

March 7, 2019

An investigation of a large performance improvement clinical database revealed that most individuals receiving CAR-T have diagnoses of ALL or large B-cell lymphoma.